identifying cost-saving opportunities. T ese insights could enable more sophisticated negotiations with pharmaceutical companies. Yet, as pharma companies also adopt AI, the negotiation landscape may become more complex, requiring continuous innovation from PBMs to maintain cost effi ciencies.


Streamlining Prior Authorization Processes T e prior authorization (PA) process,


a signifi cant pain point in managed care pharmacy, oſt en delays patient access to medications. AI has the potential to automate this process entirely by integrating it directly into the provider’s electronic health record (EHR) workfl ow. Advanced AI tools could record patient-provider interactions during offi ce or virtual visits, assist with auto-transcribed note-taking, and help answer PA approval criteria questions in real-time. T is integration would provide immediate approval or denial feedback, ensuring that when the patient arrives at the pharmacy, coverage determination has already been established. As a result, the administrative burden on pharmacists and prescribers would be reduced, treatment delays minimized, and patient outcomes improved.


Personalizing Medication T erapy Management AI can enhance Medication T erapy


Management (MTM) by predicting patient risks and enabling proactive interventions. Managed care pharmacists could use AI-driven insights to personalize care, improve adherence, and reduce adverse events, aligning with the goals of improving outcomes and reducing costs.


Enhancing Fraud Detection and Compliance AI’s ability to detect patterns and


anomalies makes it a valuable tool for identifying fraudulent activities and ensuring regulatory compliance. PBMs can use AI to monitor transactions in real- time, fl ag suspicious activities, and reduce fraud, addressing the increasing demand for transparency.


Challenges and Ethical Considerations While AI off ers signifi cant benefi ts, it also presents challenges, such as algorithmic bias


in formulary design and drug management. Human oversight will be critically important to ensure that AI systems prioritize patient outcomes over cost savings. Ethical considerations must be addressed as AI- driven processes become more integrated into healthcare.


Impact on Workforce and Operational Dynamics AI’s adoption in PBMs and managed


care pharmacy could lead to notable shiſt s in workforce dynamics. In clinical review departments, where workfl ows are standardized, AI could replace many roles, prompting managed care pharmacists to concentrate more on clinical decision- making and patient engagement. New roles centered on AI oversight and data analysis will likely emerge, requiring pharmacists to develop new skills. As these changes unfold, ongoing education and training will be essential to ensure that pharmacists can eff ectively navigate and contribute to an AI- driven healthcare environment.


T e Future of Managed Care Pharmacy in an AI-Driven World As AI progresses, its impact on PBMs


and managed care pharmacy will deepen, leading to a more data-driven, effi cient, and personalized approach to managing drug benefi ts. Navigating the ethical and operational challenges while focusing on patient care will be key for PBMs and managed care pharmacies in shaping the future of healthcare.


T e Impact of AI on the Pharmaceutical Industry As AI continues to evolve and take-hold,


its integration into the pharmaceutical industry is expected to transform various stages of the drug development and commercialization lifecycle. From early-stage research to post-market surveillance, AI’s capabilities will enhance effi ciency, lower costs, and accelerate innovation. Still, these advancements also bring challenges that the industry must address to fully harness AI’s potential.


Accelerating Drug Discovery and Development One of the most signifi cant impacts of AI in the pharmaceutical industry is


18 Missouri PHARMACIST | Volume 98, Issue III | Fall 2024


its ability to accelerate drug discovery and development. AI algorithms can analyze vast datasets to identify potential drug candidates, predict their effi cacy, and optimize molecular structures. A groundbreaking example is AlphaFold 3, an advanced AI system developed by Google DeepMind in collaboration with Isomorphic Labs. AlphaFold 3 not only predicts the 3D structures of proteins with unprecedented accuracy but also models interactions with other biomolecules like DNA, RNA, and ligands. T is enhanced capability allows researchers to gain deeper insights into molecular mechanisms, further accelerating the identifi cation of viable drug targets and facilitating the development of more eff ective therapies. Additionally, AI can streamline clinical


trial design by identifying the most promising patient populations, predicting outcomes, and monitoring trial data in real-time. Combined with advancements in preclinical testing methods, such as the use of organoids—miniature, simplifi ed versions of organs grown in vitro—these technologies signifi cantly accelerate the drug development process and reduce associated costs. T ese advancements enable pharmaceutical companies to bring new therapies to market more quickly, potentially improving patient outcomes and expanding access to innovative treatments.


Pharma’s Day in the Sun with a Surge of Novel T erapeutics With the application of AI, the


pharmaceutical industry is entering a period of rapid innovation, leading to what I believe will be pharma’s day in the sun—an explosion of novel therapeutics. T is golden era of pharmaceutical breakthroughs will be particularly signifi cant in the development of treatments for numerous orphan and rare conditions, areas that have traditionally been underserved. AI will also pave the way for curative gene therapies, off ering transformative solutions that not only treat but potentially cure diseases at their genetic root. Moreover, AI could catalyze advancements


in select established disease areas that have not been primary R&D focuses in recent years, reinvigorating research and development eff orts in these fi elds. T is shiſt could ultimately broaden treatment


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48